Philippova J, Shevchenko J, Sennikov S
Front Immunol. 2024; 15:1371345.
PMID: 38558810
PMC: 10979305.
DOI: 10.3389/fimmu.2024.1371345.
Pham D, Pham T, Bui T, Britikova E, Britikov V, Bocharov E
Mol Biol Rep. 2024; 51(1):130.
PMID: 38236367
DOI: 10.1007/s11033-023-09036-6.
di Leandro L, Colasante M, Pitari G, Ippoliti R
Toxins (Basel). 2023; 15(12).
PMID: 38133203
PMC: 10748335.
DOI: 10.3390/toxins15120699.
Nguyen M, Kim D, Shim H, Ta H, Vu T, Nguyen T
Mol Cells. 2023; 46(12):764-777.
PMID: 38052492
PMC: 10701305.
DOI: 10.14348/molcells.2023.0155.
Truex N, Rondon A, Rossler S, Hanna C, Cho Y, Wang B
ACS Cent Sci. 2023; 9(9):1835-1845.
PMID: 37780364
PMC: 10540291.
DOI: 10.1021/acscentsci.3c00625.
Design, optimization, production and activity testing of recombinant immunotoxins expressed in plants and plant cells for the treatment of monocytic leukemia.
Knodler M, Frank K, Kerpen L, Buyel J
Bioengineered. 2023; 14(1):2244235.
PMID: 37598369
PMC: 10444015.
DOI: 10.1080/21655979.2023.2244235.
Enabling the formation of native mAb, Fab' and Fc-conjugates using a bis-disulfide bridging reagent to achieve tunable payload-to-antibody ratios (PARs).
Thoreau F, Rochet L, Baker J, Chudasama V
Chem Sci. 2023; 14(14):3752-3762.
PMID: 37035695
PMC: 10074397.
DOI: 10.1039/d2sc06318b.
Tumor-specific intracellular delivery: peptide-guided transport of a catalytic toxin.
Allred C, Gormley C, Venugopal I, Li S, McGuire M, Brown K
Commun Biol. 2023; 6(1):60.
PMID: 36650239
PMC: 9845330.
DOI: 10.1038/s42003-022-04385-7.
Bacteria-derived chimeric toxins as potential anticancer agents.
Khoshnood S, Fathizadeh H, Neamati F, Negahdari B, Baindara P, Abdullah M
Front Oncol. 2022; 12:953678.
PMID: 36158673
PMC: 9491211.
DOI: 10.3389/fonc.2022.953678.
Do Bacteria Provide an Alternative to Cancer Treatment and What Role Does Lactic Acid Bacteria Play?.
Dicks L, Vermeulen W
Microorganisms. 2022; 10(9).
PMID: 36144335
PMC: 9501580.
DOI: 10.3390/microorganisms10091733.
The Role of RNA-Binding Proteins in Hematological Malignancies.
Aguilar-Garrido P, Otero-Sobrino A, Navarro-Aguadero M, Velasco-Estevez M, Gallardo M
Int J Mol Sci. 2022; 23(17).
PMID: 36076951
PMC: 9455611.
DOI: 10.3390/ijms23179552.
Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity.
Ataee M, Mirhosseini S, Mirnejad R, Rezaie E, Mahmoodzadeh Hosseini H, Amani J
Res Pharm Sci. 2022; 17(4):428-444.
PMID: 36034078
PMC: 9400466.
DOI: 10.4103/1735-5362.350243.
in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives.
Pang Z, Gu M, Tang T
Front Oncol. 2022; 12:891187.
PMID: 35574361
PMC: 9095937.
DOI: 10.3389/fonc.2022.891187.
Strategies for Heterologous Expression, Synthesis, and Purification of Animal Venom Toxins.
Rivera-de-Torre E, Rimbault C, Jenkins T, Sorensen C, Damsbo A, Saez N
Front Bioeng Biotechnol. 2022; 9:811905.
PMID: 35127675
PMC: 8811309.
DOI: 10.3389/fbioe.2021.811905.
Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin.
Havaei S, Aucoin M, Jahanian-Najafabadi A
Front Oncol. 2022; 11:781800.
PMID: 34976821
PMC: 8716853.
DOI: 10.3389/fonc.2021.781800.
DT389-YP7, a Recombinant Immunotoxin against Glypican-3 That Inhibits Hepatocellular Cancer Cells: An In Vitro Study.
Hashemi Yeganeh H, Heiat M, Kieliszek M, Alavian S, Rezaie E
Toxins (Basel). 2021; 13(11).
PMID: 34822533
PMC: 8617615.
DOI: 10.3390/toxins13110749.
Polymeric Nanoparticles for Mitochondria Targeting Mediated Robust Cancer Therapy.
Sun Y, Yang Q, Xia X, Li X, Ruan W, Zheng M
Front Bioeng Biotechnol. 2021; 9:755727.
PMID: 34692665
PMC: 8526929.
DOI: 10.3389/fbioe.2021.755727.
A Computational Approach to Modeling an Antagonistic Angiogenic VEGFR1-IL2 Fusion Protein for Cancer Therapy.
Shafique Q, Rehman H, Zaheer T, Tahir R, Bhinder M, Gul R
Bioinform Biol Insights. 2021; 15:11779322211043297.
PMID: 34566410
PMC: 8458685.
DOI: 10.1177/11779322211043297.
New Immunotherapeutic Approaches for Glioblastoma.
Vazquez Cervantes G, Gonzalez Esquivel D, Gomez-Manzo S, Pineda B, la Cruz V
J Immunol Res. 2021; 2021:3412906.
PMID: 34557553
PMC: 8455182.
DOI: 10.1155/2021/3412906.
Targeted Toxins for the Treatment of Prostate Cancer.
Wolf P
Biomedicines. 2021; 9(8).
PMID: 34440190
PMC: 8391386.
DOI: 10.3390/biomedicines9080986.